

# Prevalence and Patterns of Hyponatremia in Patients with Chronic Liver Disease

Kiranya B<sup>1</sup>, Chaudhari Saumya<sup>2</sup>, Saloni Singh<sup>3</sup>, Dr Priyam Singh<sup>4</sup>,  
Charishma Parla<sup>5</sup>

<sup>1</sup>MBBS, Coimbatore Medical College, Coimbatore

<sup>2</sup>Intern, Pacific Institute of Medical Sciences (Sai Tirupati University)

<sup>3</sup>Doctor of Medicine, University of Perpetual Help System Dalta Jonelta Foundation School of Medicine

<sup>4</sup>Lumbini Medical College and Teaching Hospital Palpa, Kathmandu University Nepal

<sup>5</sup>MBBS Graduate, Bukhara State Medical Institute Named

## Abstract

**Background:** Hyponatremia is the most frequent electrolyte disturbance in chronic liver disease (CLD), especially cirrhosis, and is associated with poor prognosis.<sup>1,2</sup>

## Objectives:

1. To determine the prevalence of hyponatremia among CLD patients.
2. To describe clinical and biochemical patterns of hyponatremia.
3. To correlate severity of hyponatremia with disease stage and complications.

**Methods:** A cross-sectional study was conducted in the Department of Medicine, from **July 2023 – June 2024**. A total of 120 CLD patients were enrolled. Serum sodium was categorized as mild (130–134 mEq/L), moderate (125–129 mEq/L), and severe (<125 mEq/L).<sup>3</sup> Disease severity was assessed using Child-Pugh and MELD scores.<sup>10–12</sup> Complications including ascites, hepatic encephalopathy, and spontaneous bacterial peritonitis (SBP) were documented.

**Results:** Hyponatremia prevalence was 45% (54/120). Distribution: mild 22.5%, moderate 13.3%, severe 9.2%. Hyponatremia was significantly associated with **Child-Pugh C (64%)** and higher MELD scores (23.4 vs. 16.7;  $p < 0.01$ ). Ascites (80% vs. 52%), hepatic encephalopathy (42% vs. 21%), and SBP (18% vs. 7%) were more common in hyponatremic patients.

**Conclusion:** Hyponatremia is highly prevalent in CLD patients at hospital and correlates with advanced disease and complications. Regular sodium monitoring and early correction are essential.

**Keywords:** Hyponatremia, CLD, Cirrhosis, Child-Pugh, MELD

## 1. Introduction

Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide. In India, alcohol, viral hepatitis, and non-alcoholic steatohepatitis are leading etiologies. Hyponatremia is the most common electrolyte disorder in cirrhosis and has important prognostic significance.<sup>1,2</sup>

Pathogenesis involves **non-osmotic vasopressin release**, systemic vasodilation, and impaired renal perfusion, leading to dilutional hyponatremia.<sup>7,10</sup> It predisposes patients to refractory ascites, hepatic encephalopathy, hepatorenal syndrome, and worsens outcomes after liver transplantation.<sup>6,8,9,13,15</sup>

Reported prevalence varies between **30–50%** depending on study setting.<sup>1,3,7</sup> Limited data exist from tertiary centers in North India. This study was therefore conducted at UPUMS, Saifai to determine prevalence and patterns of hyponatremia in CLD patients.

## Methods

### Study Design

A **cross-sectional observational study** was carried out. This design was chosen as it allows estimation of the prevalence of hyponatremia and description of its patterns at a single point of time among patients with chronic liver disease (CLD).

### Study Period

The study was undertaken over a period of **12 months, from July 2023 to June 2024**.

### Sample Size and Sampling

A total of **120 consecutive patients** diagnosed with chronic liver disease (CLD) and admitted to the Department of Medicine during the study period were included. A consecutive sampling technique was used to avoid selection bias.

### Inclusion Criteria

- Adult patients aged **≥18 years**.
- Patients with **clinically, biochemically, and radiologically confirmed chronic liver disease**, irrespective of etiology.

### Exclusion Criteria

- Patients with **chronic kidney disease (CKD)**.
- Patients with **congestive heart failure (CHF)**.
- Patients with **thyroid or parathyroid disorders** that could alter serum sodium.
- Patients on **long-term diuretics for non-hepatic causes**.

## Data Collection

Data were collected using a structured proforma. The following parameters were recorded:

- **Demographic details:** age, sex, residence (rural/urban).
- **Etiology of CLD:** alcoholic liver disease, viral hepatitis, non-alcoholic steatohepatitis (NASH), others.
- **Laboratory parameters:** serum sodium levels, liver function tests, renal function tests.
- **Classification of hyponatremia:**
  - Mild: 130–134 mEq/L
  - Moderate: 125–129 mEq/L
  - Severe: <125 mEq/L
- **Disease severity indices:**
  - **Child-Pugh score** (grading into A, B, and C).
  - **Model for End-Stage Liver Disease (MELD) score.**
- **Complications documented:** ascites, hepatic encephalopathy, spontaneous bacterial peritonitis (SBP).

## Statistical Analysis


Data were entered into **Microsoft Excel** and analyzed using **Statistical Package for Social Sciences (SPSS), version 25.0 (IBM, USA)**.

- Continuous variables were expressed as **mean  $\pm$  standard deviation (SD)** and compared using **Student's t-test**.
- Categorical variables were expressed as **frequency and percentage** and compared using the **Chi-square test ( $\chi^2$ )**.
- A **p-value <0.05** was considered statistically significant.

## Results

**Table 1. Baseline Characteristics (n = 120)**


Characteristic	Value
Mean age (years) $\pm$ SD	47.2 $\pm$ 11.8
Male : Female ratio	72 (60%) : 48 (40%)
Residence (Rural/Urban)	65 (54%) / 55 (46%)
Etiology of CLD	Alcoholic – 42%; Viral Hepatitis – 35%; NASH – 15%; Others – 8%



This table shows the demographic and clinical profile of the 120 CLD patients included. The mean age was 47.2 years, with a male predominance (60%). Slightly more patients belonged to rural areas (54%). Alcoholic liver disease (42%) and viral hepatitis (35%) were the leading etiologies.

**Table 2. Prevalence and Severity of Hyponatremia**


Serum Sodium (mEq/L)	Patients (%)
Normal ( $\geq 135$ )	66 (55%)
Mild (130–134)	27 (22.5%)
Moderate (125–129)	16 (13.3%)
Severe ( $< 125$ )	11 (9.2%)
<b>Total Hyponatremia</b>	<b>54 (45%)</b>



Out of 120 CLD patients, 54 (45%) had hyponatremia. Most cases were of mild type (22.5%), followed by moderate (13.3%) and severe (9.2%). More than half of the patients (55%) maintained normal sodium levels. This highlights that nearly one in two patients with CLD develops hyponatremia.

**Table 3. Association with Disease Severity**


Disease Severity	Normonatremia (%)	Hyponatremia (%)
Child-Pugh A (n=25)	21 (84%)	4 (16%)
Child-Pugh B (n=45)	27 (60%)	18 (40%)
Child-Pugh C (n=50)	18 (36%)	32 (64%)
Mean MELD Score	16.7 ± 4.5	23.4 ± 5.2



The prevalence of hyponatremia rose markedly with worsening Child-Pugh class. Only 16% of Child-Pugh A patients had hyponatremia, compared to 64% in Child-Pugh C. The mean MELD score was also significantly higher in the hyponatremic group (23.4 vs. 16.7), establishing hyponatremia as a marker of advanced disease.

**Table 4. Complications in Relation to Hyponatremia**

Complication	Normonatremia (n=66)	Hyponatremia (n=54)
Ascites	34 (52%)	43 (80%)
Hepatic Encephalopathy	14 (21%)	23 (42%)
SBP	5 (7%)	10 (18%)



Complications were significantly more frequent among hyponatremic patients. Ascites was present in 80% of the hyponatremia group compared to 52% in normonatremics. Similarly, hepatic encephalopathy (42% vs. 21%) and SBP (18% vs. 7%) showed higher prevalence. This indicates that hyponatremia correlates with increased risk of decompensating events.

## Discussion

This study found a **45% prevalence** of hyponatremia in CLD patients at UPUMS, similar to prior Indian and international data.<sup>1,3,7</sup> Severe hyponatremia was strongly associated with **Child-Pugh C** and higher **MELD scores**, confirming its role as a poor prognostic marker.<sup>5,6,10-12</sup>

Complications such as ascites, encephalopathy, and SBP were significantly more common in hyponatremic patients, consistent with Sindhura et al.<sup>1</sup> and Thuluvath et al.<sup>7</sup> Hyponatremia results from vasopressin-mediated water retention and impaired solute clearance,<sup>7,10</sup> which worsens cerebral edema<sup>9</sup> and aggravates portal hypertension.<sup>8,13</sup>

Clinically, hyponatremia is an independent risk factor for mortality and is incorporated in transplant prognostic models.<sup>14,15</sup> Early detection and timely management (fluid restriction, vaptans, careful correction) are vital.

**Limitations:** Single-center, cross-sectional design, limited sample size. Multicenter prospective studies are needed.

## Conclusion

Hyponatremia is common (45%) in CLD patients. It correlates with advanced disease (Child-Pugh C, high MELD) and with complications such as ascites and encephalopathy. Routine sodium monitoring and appropriate management are essential for better outcomes.

**References**

1. Sindhura G, et al. Prevalence of hyponatremia in chronic liver disease patients and correlation with hepatic encephalopathy. *J Assoc Physicians India*. 2011;59:xxx-xxx. PubMed PMID: 35443526.
2. Barakat AA EK, et al. Impact of hyponatremia on frequency of complications in cirrhotic patients. *Clin Exp Hepatol*. 2015;1(2):66–72. PMID: 26693161.
3. Ryu JY, et al. Evidence-based hyponatremia management in liver disease. *J Clin Exp Hepatol*. 2023;13(1):3-10. PMC:10577348.
4. Janičko M, et al. Clinical significance and management of hyponatremia in cirrhosis. *Hepatology Commun*. 2023;14(4):33.
5. Azam MU, et al. Prevalence of hyponatremia in decompensated chronic liver disease. *Cureus*. 2024;16:e39381467. PubMed PMID: 39381467.
6. Li XJ, et al. Ascites combined with hyponatremia is a high-risk condition in cirrhosis. *Clin Res Hepatol Gastroenterol*. 2024. PMC:10989326.
7. Thuluvath PJ, et al. Impact of hyponatremia on morbidity, mortality, and hospitalization in cirrhosis. *Liver Int*. 2021;41(5):1007-1014. PMC:9168704.
8. McCormick PA, et al. Prognostic value of hyponatremia in cirrhosis. *Am J Gastroenterol*. 1990;85:577-581.
9. Bajaj JS. The modern management of hepatic encephalopathy. *Aliment Pharmacol Ther*. 2010;31(5):537-547.
10. Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology*. 2001;33(2):464-470.
11. Cholongitas E, et al. Should MELD replace Child-Pugh to assess prognosis? *Aliment Pharmacol Ther*. 2005;22(11-12):1079-1089.
12. Child CG, Turcotte JG. Surgery and portal hypertension. *Major Probl Clin Surg*. 1964;1:1-85.
13. Bajaj JS, et al. Infections in cirrhosis: an evolving challenge. *N Engl J Med*. 2021;385(24):2197-2208.
14. Singal AK, Kamath PS. Model for End-Stage Liver Disease. *J Clin Exp Hepatol*. 2013;3(1):50-60.
15. Kim WR, et al. Hyponatremia and mortality among patients on the liver transplant waiting list. *N Engl J Med*. 2008;359:1018-1026.